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Abstract
Background: Cigarette smoke causes both acute and chronic changes of the immune system. Excluding recent smoking is
therefore important in clinical studies with chronic inflammation as primary focus. In this context, it is common to ask the
study subjects to refrain from smoking within a certain time frame prior to sampling. The duration of the smoking cessation
is typically from midnight the evening before, i.e. 8 hours from sampling. As it has been shown that a proportion of current
smokers underestimates or denies smoking, objective assessment of recent smoking status is of great importance. Our aim
was to extend the use of exhaled carbon monoxide (CObreath), a well-established method for separating smokers from non-
smokers, to assessment of recent smoking status.
Methods and Findings: The time course of CObreath decline was investigated by hourly measurements during one day on
non-symptomatic smokers and non-smokers (6+7), as well as by measurements on three separate occasions on non-
smokers (n=29), smokers with normal lung function (n=38) and smokers with chronic obstructive pulmonary disease
(n=19) participating in a clinical study. We used regression analysis to model the decay, and receiver operator
characteristics analysis for evaluation of model performance. The decline was described as a mono-exponential decay
(r
2=0.7) with a half-life of 4.5 hours. CO decline rate depends on initial CO levels, and by necessity a generic cut-off is
therefore crude as initial CObreath varies a lot between individuals. However, a cut-off level of 12 ppm could classify recent
smokers from smokers having refrained from smoking during the past 8 hours with a specificity of 94% and a sensitivity of
90%.
Conclusions: We hereby describe a method for classifying recent smokers from smokers having refrained from smoking for
.8 hours that is easy to implement in a clinical setting.
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Introduction
Smoking is a major factor in heart disease, stroke and chronic
lung disease, and the association of smoking with altered levels of
inflammatory markers is well documented [1,2,3]. It is known that
inflammatory markers have a temporal relationship to smoking
[4,5,6], and that the acute effects of cigarette smoke have an
impact on a number of cellular and biochemical measures in the
lung [7,8]. Thus, in studies focusing on chronic inflammation of
the lung, such as mechanistic investigations of chronic obstructive
pulmonary disease (COPD) and rheumatoid arthritis, the acute
inflammatory effects of smoking is a confounding factor. In this
context it is common to ask the study subjects to refrain from
smoking within a certain time frame prior to sampling. The
duration of the smoking cessation is typically from midnight the
evening before, i.e. no smoking within 8 hours from sampling.
However, as it has been shown that a proportion of current
smokers underestimates or denies smoking [9,10], the ability to
objectively assess recent smoking status is of great importance.
Objective measures of smoking status include cotinine levels in
urine, however the half-life of cotinine is 17 hours [11] and hence
more suitable for distinguish smokers from non-smokers, not to
assess recent smoking status among smokers [12]. Measuring
carbon monoxide in exhaled breath (CObreath) is an immediate,
non-invasive and well-established method used to classify smokers
from non-smokers [13,14]. As a constituent of cigarette smoke,
carbon monoxide enters the circulation during smoking and forms
carboxyhemoglobin (COHb). The elimination of CO is primarily
by respiration thus there is a strong correlation between CObreath
and COHb [10,13,15] making it a useful tool for assessing
smoking status. Depending on factors such as gender and physical
activity [16], COHb half-life is 5–6 hours [15,17] and is thus more
suitable for estimating short term smoking abstinence. Moreover,
CObreath is correlated to the number of cigarettes smoked during
the past 24 hours [18,19,20] as well as to the time since last
cigarette smoked [19].
A number of cut-off levels ranging from 5–6 ppm depending on
study population have been suggested for classification of smokers
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method for using CObreath to assess recent smoking status among
smokers. In this study, we have investigated whether exhaled
carbon monoxide can be used as a tool to discriminate between
short term abstinence and continued smoking. Our aim was to
establish a cut off value for CObreath to be used for discriminating
recent smokers from smokers having refrained from smoking for at
least 8 hours.
Materials and Methods
Investigating CObreath Decline: Subjects and Study
Design
Group 1: Model group. A training set of 13 individuals was
used for modelling of CObreath decline over an 8 hour period. The
model group consisted of 6 non-symptomatic current smokers and
7 non-smokers aged 45–66 years (Table 1). They had no self-
reported airway symptoms and were not taking any medication.
The subjects were allowed to smoke at one occasion in the
morning, and thereafter the CObreath levels were measured hourly
throughout the day as the subjects refrained from smoking.
Baseline CObreath levels measured prior to smoking as well as
CObreath levels measured immediately after smoking were also
assessed. The participants were instructed on how to use the
portable CO monitor and then performed measurements on their
own (see below).
Group 2: Test group. A test set of 86 individuals was used to
evaluate the model constructed from the training set. The test
group were participants of a clinical study at the Karolinska
University Hospital Solna, Sweden, (Table 2) and consisted of
healthy non-smokers (n=29), current smokers with normal lung
function (n=38), and current smokers with COPD of GOLD
stage I and II (mild to moderate disease) (n=19) [23]. In COPD
patients, the ratio FEV1/FVC (FEV1: forced expiratory volume in
1 second; FVC: forced vital capacity) was ,0.7 and FEV1 was 50–
100% of predicted after inhalation of two doses of terbutaline a `
0.5 mg (Bricanyl TurbuhalerH, AstraZeneca AB, So ¨derta ¨lje,
Sweden). All smokers of group 1 and 2 had a smoking history of
.10 pack years and a current cigarette consumption of .10
cigarettes/day. The COPD patients had not undergone any oral
or inhaled corticosteroid treatment for the last 3 months and had
not experienced any signs of disease worsening (exacerbation)
within the past 3 months. In addition, in vitro screening for the
presence of specific IgE antibodies against common inhaled
allergens (PhadiatopH, Pharmacia-Upjohn, Uppsala, Sweden) was
negative in all participants. CObreath measurements were assisted
by a research nurse at scheduled visits at the clinic (3–4 separate
occasions/individual), at which point the study subjects were asked
to estimate time since last cigarette smoked (see below). Body mass
index (BMI), blood haemoglobin and high sensitive C-reactive
protein (CRP) level were determined during visits.
Ethics Statement
The study was approved by the local ethical board (Stockholm,
Sweden; ethical committee diary number 2006/959-31/1) and
performed in accordance with the Declaration of Helsinki.
Informed, written consent was obtained from all study partici-
pants.
Measurement of Exhaled CO (CObreath)
CObreath levels were measured in triplicate at each time point
using the SmokerlyzerH Micro EC50 device (Bedfont Scientific
Ltd, Kent, U.K.) according the manufacturer’s recommendations.
In brief, subjects were asked to hold their breath for 20 seconds to
allow COHb to form equilibrium with alveolar CO. The subjects
then exhaled slowly and fully into the mouthpiece of the
instrument during which CObreath was recorded. The CObreath
levels are given in parts per million (ppm). The device was
calibrated according to the manufacturer’s instructions prior to
use, and then biannually throughout the study.
Statistical Analyses and Modelling
Statistical analysis was performed using GraphPad Prism
version 5.02 (GraphPad Software Inc., USA). Mean of triplicate
measurements, standard deviation (SD) and coefficient of variance
(CV) were calculated for each time point. Differences between 2
groups were investigated using Mann-Whitney test. Comparisons
between 3 groups were calculated using Kruskal-Wallis analysis of
variance followed by Dunn’s post-test. Correlations were calcu-
lated according to Spearman’s rank correlation (p ,0.05 was
considered statistically significant).
To investigate CO decline over time, nonlinear regression was
used on the raw data from group 1. A mono-exponential equation
[Y=Y0*exp(2K*x)], where Y=ppm CObreath at time x hours
since smoking, Y0=CObreath immediately after smoking (i.e. at
x=0) and x=time elapsed since last cigarette was used to model
the decay. The validity of the mono-exponential equation was
tested by plotting the natural logarithm of CObreath (ln(CObreath))
versus time followed by a linearity test using linear regression
analysis [24]. CObreath half-life was calculated as ln(2)/slope.
Prediction limits (95%) for the model were calculated and
evaluated as cut-offs. To evaluate the robustness of the model
and the generated cut-off, cross validation was performed by
dividing the non-symptomatic smokers in group 2 into six cross-
validation sets, each consisting of a randomly selected training set
(n=30) and test set (n=8).
Receiver-operator characteristics (ROC) analysis for CObreath
was performed using GraphPad Prism version 5.02 and Excel
(Microsoft, Redmond, OR, USA), and sensitivity and specificity
levels were calculated. To evaluate the robustness of the ROC
analysis, the analysis was performed 6 times and each time 8
randomly selected individuals were excluded from the analysis.
Results
Exhaled CO in Smokers versus Non-smokers
In line with previous findings, CObreath levels were significantly
higher in smokers (.8 hours after last cigarette) than in non-
smokers in both study groups (Figure 1A and B). No significant
difference in breath CO was observed comparing smokers with
normal lung function and smokers with COPD, GOLD stage I–II
Table 1. Characteristics for non-smokers and smokers (group
1).
Variable Non-smokers (n=7) Smokers (n=6)
Age 60 (48–66) 56 (45–65)
Sex
Female 43
Male 33
Pack years 0 27.5 (22–34)
Cig/day past 6 months. 0 15 (10–20)
Values are given as median (range). Pack years=(number cigarettes smoked per
day)/(content of 1 packet of cigarettes (20)) * years as a smoker.
doi:10.1371/journal.pone.0028864.t001
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measurements was 8.8% and 10.2% for non-symptomatic smokers
and smokers with COPD, respectively. The high relative variance
for non-smokers (CVmedian=150%) was explained by the overall
low absolute values (0–3 ppm) close to the detection limit.
Time Course of CObreath Decline
Group 1. CObreath measurements from smoking subjects
(n=6) were plotted versus time since smoking. The CObreath
levels measured in the morning 8 hours since smoking were higher
than those measured in the afternoon 8 hours since smoking. For
all smokers, CObreath levels measured in the morning exceeded 6
ppm. Non-smokers (n=7) had CObreath levels below 3 ppm
regardless of the time-of-day, with slightly elevated CObreath at
lunchtime (Figure S1). In smokers, CObreath decline could be
described as a mono-exponential decay (Y=(Y0-0.35)*e
20.366
+0.35; r
2=0.77, Figure 2A). Logarithmic values, ln(CObreath),
were plotted versus time since smoking (Figure 2B). Linear
regression on the time course from each individual subject gave r
2
values 0.5; 0.8; 0.8; 0.9; 0.9 and 0.9, respectively. The differences
in decline rate were not statistically significant (p=0.2), but the
difference between the y-intercepts (initial CObreath levels) were
(p,0.0001). Given that the decline rates were similar, CO half-
life was determined from the merged linear regression of all
subjects (Y=2.6-0.1536,r
2=0.7) giving a CO breath half-life of
4.5 hours.
Table 2. Characteristics and lung function data for non-smokers, smokers with normal lung function and smokers with COPD
(group 2).
Variable
Non-smokers with normal
lung function (n=29)
Smokers with normal
lung function (n=38)
Smokers with
COPD (n=19)
Age 59 (46–66) 52 (44–65) 57 (47–62)
Sex
Female 15 20 9
Male 14 18 10
Pack years # 0 34 (15–49) 42 (23–62)
Cig/day past 6 months. 0 20 (10–40) 20 (2.5–25)
FEV1, % of predicted #¤ 119 (89–141) 106.5 (91–140) 52 (51–97)
FEV1/FVC # ¤ 0.82 (0.70–0.91) 0.78 (0.71–0.88) 0.61 (0.45–0.69)
DLCO * ¤ 92 (74–116) 80 (48–106) 68 (50–81)
Values are given as median (range). Statistically significant differences (p,0.05) between groups are indicated * (Non-smokers vs Smokers), # (Smokers with COPD vs
Smokers) and ¤ (Smokers with COPD vs Non-smokers).
FEV1: Forced expiratory volume in 1 second, measured post-bronchodilator.
FVC: Forced vital capacity, measured post-bronchodilator.
DLCO: Carbon monoxide diffusion capacity.
doi:10.1371/journal.pone.0028864.t002
Figure 1. Baseline CObreath levels measured on non-smokers, smokers with normal lung function and smokers with COPD. A.
CObreath from smokers and non-smokers recruited for a time course study of CObreath decline (group 1). CObreath (ppm) was measured in the morning;
smokers having refrained from smoking during the past .8 hours. ** indicates p,0.01. B. CObreath measured on smokers with normal lung function
(‘‘smokers’’), smokers with COPD and non-smokers with normal lung function (group 2). CObreath (ppm) was measured in the morning; smokers
having refrained from smoking during the past 8 hours. *** indicates p,0.001.
doi:10.1371/journal.pone.0028864.g001
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prior to smoking were found to be higher compared to those
measured at the corresponding time point after smoking in the
afternoon. The magnitude of the difference was determined to be
a factor of 1.33 in group 1 (Figure S1B). A likely reason for the
observed difference is differences in ventilation rate during the day
compared to the night (see Discussion). Under the assumption that
the CObreath decline for group 2 corresponded to that of group 1,
the normalization factor of 1.33 was used to adjust for diurnal
differences in decline rate also in group 2.
Group 2. No significant differences in CObreath decline
pattern was detected between non-symptomatic smokers and
smokers with COPD. As the self-reported time since smoking
varied between individuals, the recorded data was merged into 4
intervals; 0.2560.25, 160.5, 961 and 1662 hours since smoking
(Figure S2). The differences between these time-bins in terms of
gender were evaluated. CObreath levels from both men and women
declined significantly from 160.5 to 961 hours (p,0.0001). The
CObreath decline from 0.2560.25 to 160.5 hours was however not
large enough to be statistically significant. At time bin 961
(measurement performed in the morning after having refrained
from smoking during the night), women had significantly lower
CObreath compared to men (p,0.05). No differences in exact time
since smoking or differences in current cigarette consumption
could explain these observations. To further investigate CObreath
decline over time, ln(CObreath) was plotted against time since
smoking. When calculated separately, CObreath half-life differed
between men and women (9.5 and 7.2 hrs, respectively) within the
time interval 0–18 hrs. Given that the differences in decline rate
were non-significant, CObreath data from men and women were
merged in subsequent calculations.
As described under ‘‘Normalisation’’, CObreath measurements
performed in the morning on smokers in group 2 were adjusted by
dividing with a factor 1.33. This gave a constructed decline rate
corresponding to that of group 1. The robustness of the
constructed decline rate was tested by a six-fold randomized cross
validation within group 2 and showed similar decline rates in all
rounds. The average slope of the decline and upper 95%
prediction limit (Y=3.9-0.166) are shown in Figure 3A. From
the constructed decline rate, CObreath half-life was estimated to
4.3 hours. The log-transformed decay model (ln(CObreath)o f
normalized values was further evaluated using the subgroup of
smokers diagnosed with COPD (n=19) as a test set. No significant
difference between smokers and COPD patients were detected,
neither in terms of slopes nor intercepts.
Smoking History, Age and Lung Function
Smokers with normal lung function: there was a weak
correlation between CObreath and the number of cigarettes
smoked per day during the past 6 months, but not to the
cumulative smoking history in pack years or between CObreath at
8 hours since smoking and absolute total lung capacity (TLC),
Figure S3. No correlations were found between CObreath at
8 hours since smoking and age, FEV1 (absolute or percent of
predicted), TLC% of predicted, body mass index (BMI), blood
haemoglobin or CRP levels. No significant correlations to the
above parameters were detected for smokers with COPD.
Model Performance
A cut-off of 12 ppm based on the averaged upper prediction
limit at 8 hours since smoking (Figure 3A; Y=3.9-0.166) for
classifying recent smokers was validated using ROC curves
(Figure 3B). At a cut-off of 12 ppm the average sensitivity was
90% and the specificity 94% for classifying recent smokers from
smokers who had abstained from smoking for at least 8 hours. The
robustness of the model was evaluated through 6 ROC curves in
which different parts of the dataset had been left out. AUC for
these were 0.98, 0.99, 0.91, 0.92, 0.96 and 0.94. In addition to the
above generic cut-off, we tested individualised cut-off values based
on the averaged upper prediction limit, but by utilizing also one
previous measurement from each individual. The aim of this was
to also consider the differences in Y0 values due to differences in
smoking habits among the participants. This resulted in a model
with a specificity of 95% and a sensitivity of 98% (Table S1).
Discussion
In this study, we address an issue relevant to clinical and
exploratory trials that include smoking subjects. With the aim to
establish a method for assessing recent smoking status, we have
evaluated CObreath cut-off levels to classify recent smoking status.
Specifically, a cut-off level of 12 ppm indicated whether a subject
had smoked within the past 8 hours with a sensitivity of 90% and a
specificity of 94%. The method was applied in our clinic at the
Figure 2. Time course of CObreath decline after smoking one
cigarette (group 1). A. After normalisation against each individual
peak value, relative CObreath values were plotted as a function of time
since smoking. By non-linear regression, a one phase exponential model
was fitted to the decay (Y=(Y0-0.35)*e
20.366+0.35, r
2=0.77). B. The
natural logarithm of CObreath, ln(CObreath) was plotted versus time since
smoking, and the decay was described by linear regression (Y=Y0-
0.156,r
2=0.70). From the slope, CObreath half-life during the day was
estimated to 4.5 hours (ln(2)/slope). The 95% prediction limits are also
showed in the figure (dashed lines).
doi:10.1371/journal.pone.0028864.g002
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smokers participating in a translational study on COPD.
A number of previous studies have shown that CObreath levels
can be used to classify smokers from non-smokers in clinical
settings. In the present study we expanded on these principles by
developing a method based on CObreath decline over time to assess
the time since last cigarette within a population of smokers. By
using individual cut-off values, we were able to separate smokers
who had refrained from smoking for at least 8 hours from those
who had smoked within this time frame with a specificity of 95%
and a sensitivity of 98%. However, as calculation of individual
values is impractical in a clinical setting, and requires prior
collection of at least two CObreath time points from the subject, we
also evaluated a generic cut-off value. Through a model based on
38 smokers, we found that a cut-off value of 12 ppm could
discriminate between recent smokers and smokers that have
refrained from smoking for .8 hrs with a specificity of 94% and a
sensitivity of 90%. Given that our data show that the levels of
CObreath in smokers are higher in the morning as compared to the
corresponding time points in the afternoon, the indicated cut-off is
intended for measurements performed in the morning. Although
based on relatively few observations our data suggests a faster
decline during the day, which is consistent with the findings of
others [16]. Consequently we suggest using a correction factor of
1.33 for measurements performed in the afternoon, resulting in a
cut-off of 12 ppm for studies evaluating smoking cessation during
daytime.
It is known that CO in breath can be confounded by many
factors such as diet, physical exercise, inflammatory diseases and
time of the day [16,25]. In our study, both smokers and non-
smoking controls had slightly higher CObreath at lunchtime,
presumably caused by dietary factors for which the CO detector
is cross-sensitive. As CO is produced endogenously as well,
particularly during oxidative stress and inflammation, the
potentially confounding effects of inflammatory lung disorders
such as COPD and asthma needs to be considered. A study based
on patients with asthma and COPD suggested slightly higher cut-
off values of 10–11 ppm [14] in classification of smokers from non-
smokers. However, increased levels of CO in exhaled air is
primarily associated with exacerbations of the diseases [21], and
may not be relevant for study designs where subjects without
recent exacerbations are enrolled. This was the case in our study
design, and no significant difference in CObreath was detected
when comparing smokers with normal lung function and smokers
with COPD (Figure 3A).
Eighty-five percent of CO in the body is bound to hemoglobin
in circulating erythrocytes, and the majority of the remaining CO
is bound to myoglobin in the muscles [16]. As such, the slight
gender differences in CObreath decline rate observed in group 2
may be due to differences in muscle mass resulting in differing CO
storage compartment. If this was the case, the effects would be
more pronounced at longer time point since smoking. This is
consistent with our findings where significant differences in half-
lives were observed first after 8 hours of abstinence, and could
serve as an explanation as to why the differences observed in group
2 was not seen in group 1. The relation between CObreath and time
elapsed since smoking has previously been addressed by Leitch
et al. They observed that CO decline rate depends on initial CO
levels, which is consistent with a logarithmic decrease [6], but on
average has a decline of 3.4 ppm/hour. By necessity, a generic cut-
off is therefore crude as initial CObreath varies a lot between
individuals.
A limitation with the group 2 data set is the absence of available
data points between 3–7 hours since smoking, as very few
measurements were performed within that time span. This may
bias the specificity and sensitivity calculations in both models,
resulting in an exaggerated discriminating ability. For proper
evaluation of the proposed cut-off values, additional measurements
performed in the critical time range are required. Also, the model
is based on the assumption that the participants are accurate in
their self-estimation of time since smoking. Likewise, the fact that
the data from group 2 is discontinuous in the sense that the
measurements are not limited to one day represents a possible
further limitation in the strength of the resulting model. However,
these patterns in the data set are highly reflective of the
Figure 3. Proposed model for CObreath decline (group 2), and
receiver operator characteristics (ROC) analysis for evaluation
of model classification performance on smoking subjects with
and without COPD. A. CObreath measurements (smokers) were
recorded in the morning. After normalisation ln(CObreath) was plotted
versus self-reported time since smoking. To allow comparisons with
group 1, measurements performed .8 hours since smoking were
omitted. CO decline was modelled by linear regression (solid line) on
smokers with normal lung function. From the slope, CObreath half-life
was estimated to 4.3 hours (ln(2)/slope). The 95% prediction limits are
indicated in the graph as dashed lines. The upper prediction limit
(Y=3.9-0.166) was evaluated as a cut-off. As test set, CObreath measured
on smokers with COPD (n=19) were included (indicated with triangles).
B. CObreath values measured #7 hours were used to estimate specificity
(classified as positive for recent smoking status), and values measured
between 8–10 hours since smoking were used to estimate the
sensitivity (classified as negative for recent smoking status). A cut-off
of 12 ppm gave a sensitivity of 94% and a median specificity of 97%.
Area under the curve (AUC) was 0.96. X-axis: False positive Rate, Y-axis:
True positive Rate.
doi:10.1371/journal.pone.0028864.g003
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morning of the investigation, i.e. within the past few hours of CO
monitoring, or the subject has adhered to the instructions and
refrained from smoking since the evening before the procedure,
and thus refrained from smoking for at least 8 hours.
To conclude, we propose a cut-off for classification of recent
smoking status that is higher (12 ppm CO) compared to previous
methods for classification between smokers and non-smokers. The
application of the method is in clinical studies where recent
smoking status has an impact on the outcome.
Supporting Information
Figure S1 Breath CO as measured on 6 smokers and 7
non-smokers at 1-hour-intervals during one day (group
1). After having refrained from smoking during the night
(.8 hours), exhaled CO was measured in the morning. Smokers
were allowed to smoke one cigarette and then asked to refrain
from further smoking throughout the day. A. Breath CO decline
of smokers. Generally, measurements performed in the morning
(.8 hours since smoking; dotted line indicates smoking of one
cigarette) were higher than the corresponding .8 hrs since
smoking measurements in the afternoon. B. Normalization of
diurnal differences in CO elimination rates. Plot showing the
ratios between breath CO.8 hrs since smoking measured in the
morning divided by breath CO.8 hrs since smoking measured
in the afternoon (group 1). For calculating the ratios, we used
measured values closest to 8 hours since smoking for each
individual. The derived median ratio 1.33 was used as
normalization factor in subsequent evaluations. The value in
brackets was measured 3.45 hours since smoking, and was
excluded from the calculations. C. Breath CO of smokers plotted
against the time of day. D. Breath CO of non-smokers plotted
against time of day.
(EPS)
Figure S2 Breath CO decline (smokers, group 2) plotted
against self-estimated time since last cigarette. A. Breath
CO decline plotted against self-estimated time since last
cigarette. The recordings were not performed continuously
during one day, but performed over separate days. B. CObreath
decline of smokers in terms of gender (group 2). Gender
differences (indicated using bars with hook) were significant at
the time interval 961h r s( p ,0.05), but not at any other time
point. When comparing breath CO decline in terms of distinct
time intervals (both men and women; indicated with bars), there
were significant (p,0.01) differences between each time bin
except from 0.2560.25 to 160.5. * p-value,0.05. (Mann
Whitney rank sum test).
(EPS)
Figure S3 CObreath 8 hours since smoking in relation to
current smoking history and lung capacity, respectively.
A. Breath CO and current cigarette consumption. B. Breath CO
at 8 hours since smoking and total lung capacity (TLC).
(EPS)
Table S1 Evaluation of individual cut-offs as predicted
from the equation Y=Y0-0.166 (derived from the
averaged decline rate obtained from smokers with
normal lung function, group 2).
(PDF)
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